Analyst Price Targets — KOD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 11, 2026 12:00 pm | — | Chardan Capital | $61.00 | $41.38 | TheFly | Kodiak Sciences upgraded to Buy from Neutral at Chardan |
| March 27, 2026 1:15 pm | — | UBS | $80.00 | $37.00 | TheFly | Kodiak Sciences price target raised to $80 from $50 at UBS |
| March 27, 2026 10:04 am | Matthew Caufield | H.C. Wainwright | $58.00 | $37.00 | TheFly | Kodiak Sciences price target raised to $58 from $38 at H.C. Wainwright |
| March 26, 2026 6:08 pm | — | Jefferies | $56.00 | $39.76 | TheFly | Kodiak Sciences price target raised to $56 from $39 at Jefferies |
| January 22, 2026 11:07 am | Matthew Caufield | H.C. Wainwright | $38.00 | $26.71 | TheFly | Kodiak Sciences price target raised to $38 from $26 at H.C. Wainwright |
| January 7, 2026 5:44 am | Michael Yee | UBS | $50.00 | $25.05 | StreetInsider | UBS Starts Kodiak Sciences Inc. (KOD) at Buy |
| September 25, 2025 8:34 am | Gena Wang | Barclays | $17.00 | $15.49 | TheFly | Kodiak Sciences upgraded to Equal Weight from Underweight at Barclays |
| December 9, 2024 11:09 am | Michael Yee | Jefferies | $20.00 | $11.48 | StreetInsider | Jefferies Upgrades Kodiak Sciences Inc. (KOD) to Buy |
| September 24, 2024 10:04 am | Andrea Tan | Goldman Sachs | $2.00 | $2.43 | StreetInsider | Goldman Sachs Reiterates Sell Rating on Kodiak Sciences Inc. (KOD) |
| November 14, 2022 8:46 am | — | Morgan Stanley | $9.00 | $7.59 | Benzinga | Morgan Stanley Maintains Equal-Weight on Kodiak Sciences, Lowers Price Target to $9 |
Latest News for KOD
Shares of Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shot up 6.6% on Friday. The company traded as high as $43.94 and last traded at $43.9590. Approximately 68,404 shares changed hands during trading, a decline of 92% from the average session volume of 900,653 shares. The stock had previously closed at $41.25. Wall
Kodiak Sciences (KOD) is transitioning from past clinical disappointments to a maturing retina platform with multiple near-term catalysts. Recent GLOW2 Phase 3 success for Zenkuda in diabetic retinopathy and upcoming pivotal data for Zenkuda, KSI-501, and KSI-101 underpin a bullish outlook. KOD's current $169.5M cash position supports near-term catalysts, but additional capital will be needed for commercialization…
This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.
PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KOD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.